The following stories appear in full on today's Vidyya Medical News Service Web site.
People with 21-hydroxylase deficiency a common yet little known disorder causing early puberty and masculinizing features in both males and females also lack sufficient quantities of the stress hormone adrenaline, according to a study by researchers at the National Institute of Child Health and Human Development (NICHD).
In 1994, the National Cancer Institute (NCI) began a comprehensive study
on the causes of brain tumors. The impetus for the study grew out of public
concern about cellular telephone use and adult brain tumors which led Congress
in 1993 to urge NCI to conduct the study. The study has been updated to include new information as of November, 2000.
The newest information regarding the diagnosis, histopathology and pathogenesis of brain tumors can be found in this set of abstracts. The abstracts are those that have been added to the CANCERLIT database for October, 2000. Every effort has been made to ensure the search strategy used produces the most accurate results, so that you can read the information you need quickly and get on with your day.
Each year more than 17,000 people in the United States find out they have a brain tumor. The National Cancer Institute (NCI) has written this booklet to help patients and their families and friends better understand brain tumors. We also hope others will read it to learn more about these tumors. This booklet describes the symptoms, diagnosis, and treatment of brain tumors.
TAP Pharmaceutical Products Inc. today announced that it has in-licensed FR229934, an investigational compound being studied for the treatment of erectile dysfunction (ED) from Fujisawa Pharmaceutical Co., Ltd. Under the license agreement, TAP has exclusive rights to develop this compound and market it on a worldwide basis, except for Japan, South Korea, China and the Republic of China (Taiwan).
As always, we hope you enjoy the issue.